Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability. CYP3A5*3 polymorphism is reported to be functional and may contribute to the interindividual variability. The objective of this meta-analysis was to accurately estimate the effect of CYP3A5*3 allele on CsA dose-adjusted blood concentration. A computerized literature search was conducted in PubMed. A total of 12 and 6 studies meeting the inclusion criteria were, respectively, included in meta-analysis about dose-adjusted trough concentration (C 0 /D) and dose-adjusted peak concentration (C 2 /D). The combined weighted mean difference (WMD) between CYP3A5 expressers (*1/*3 þ *1/*1) and non-expressers (*3/*3) was significant in C 2 /D (WMD ¼ À12.73 (ng ml -1 )/ (mg kg -1 ), 95% confidence interval (CI) À25.23 to À0.22, P ¼ 0.046), whereas it was marginally significant in C 0 /D (WMD ¼ À3.75 (ng ml -1 )/ (mg kg -1 ), 95% CI À7.58 to 0.07, P ¼ 0.054). Exclusion of an outlier study greatly increased the association of CYP3A5 polymorphism with C 0 /D to be significant (WMD ¼ À4.92 (ng ml -1 )/(mg kg -1 ), 95% CI: À8.27 to À1.58, P ¼ 0.011). This meta-analysis showed that CYP3A5*3 polymorphism is associated with CsA dose-adjusted concentration in renal transplant recipients. Patients carrying the CYP3A5*3/*3 genotype will require a lower dose of CsA to reach target levels compared with the CYP3A5*1/*1 or *1/*3 carriers.
Introduction
Cyclosporine (CsA) is a widely used calcineurin inhibitor to prevent allograft rejection in renal transplantation. However, CsA has a narrow therapeutic range and large inter-individual variability, which requires close therapeutic drug monitoring to improve the efficacy and reduce the toxicity. 1 In clinical practice, monitoring individual trough or peak CsA concentration is widely recommended for daily dose adjustment. 2 CsA disposition is influenced by numerous factors such as ethnicity, grapefruit juice, liver function and genetics. 3, 4 It has been identified that the metabolism of CsA is mainly mediated by cytochrome P450 3A (CYP3A). 5 Therefore, CYP3A may importantly affect CsA pharmacokinetics. CYP3A subfamily includes four isozymes: CYP3A4, CYP3A5, CYP3A7 and CYP3A43. Of them, CYP3A4 and CYP3A5 are the major enzymes accounting for metabolism of CsA. 5 CYP3A4 is abundantly and constitutively expressed in liver and intestine. 6 According to published literature, the expression of CYP3A4 is limitedly influenced by genetic factors. 7 Although a number of singlenucleotide polymorphisms for CYP3A4 have been identified, most of them are rare and not reported to affect its activity. 8 Inversely, CYP3A5 is polymorphically expressed with high activity in 50% of African Americans and in approximately 30% of Caucasians. 9 Therefore, the variable expression of CYP3A5 was supposed to be an important reason for inter-individual pharmacokinetic variability of CsA. Among several polymorphisms of CYP3A5 gene, the most common and functionally important variant is CYP3A5*3, which is designated by an A6986G transition within intron 3. Previous studies have confirmed that the replacement of A (CYP3A5*1) by G (CYP3A5*3) creates a cryptic consensus splice site and causes alternative splicing and protein truncation, resulting in the absence of protein activity. 9 As CsA is a substrate of CYP3A5, CYP3A5*3 polymorphism might contribute to inter-individual variability of CsA disposition. A high dose of CsA is supposed to be required to reach target levels for individuals with at least one CYP3A5*1 allele classified as CYP3A5 expresser.
Several lines of clinical studies have been performed to analyze the association between CYP3A5*3 polymorphism and CsA pharmacokinetics, including dose-adjusted trough concentration (C 0 /D) and dose-adjusted peak concentration (C 2 /D). Most of these studies were conducted in renal transplant patients. 10 Until now, results of these studies remain controversial. Hu et al. 11 retrospectively analyzed the effect of CYP3A5*3 polymorphism on CsA C 0 /D during the first week after renal transplantation in 106 Chinese patients. The results showed that patients carrying the CYP3A5*3/*3 or *3/*1 genotype required a lower dose of CsA to reach target trough levels when compared with the CYP3A5*1/*1 carriers. A recent study reported by Qiu et al. 12 showed that C 0 /Ds in patients with the CYP3A5*3/*3 genotype was 25.5 and 30.7% higher than those with the wild-type genotype during days 8-15 and days 16-30 after transplantation, respectively. In contrast, Wang et al. 13 failed to observe significant difference in C 0 /D of CsA between CYP3A5 expressers and non-expressers during the early stage after renal transplantation in Chinese patients. With regard to the studies performed in the steady state after transplantation, Hesselink et al.
14 reported that the CsA dose requirements were not associated with CYP3A5 genotypes at months 3 and 12 since transplantation. However, a significant association was found at month 12 when only Caucasians were considered in this study.
The reasons for these conflicting results remain unclear. It may have arisen through ethnicity of subjects, interval after transplantation, methods of pharmacokinetic assessment and sample size. Although several recent reviews have focused on the effect of CYP3A5*3 allele on CsA pharmacokinetics, conclusive results could not be drawn. 10, 15 In addition, none of these reviews used a quantitative metaanalytic approach to evaluate the association. Meta-analysis can be used to increase statistical power, reduce biases, synthesize results of past studies and get a quantitative evaluation. In the present study, we conducted a metaanalysis of all relevant published studies to evaluate the relationship between CYP3A5*3 allele and CsA dose-adjusted blood concentration in renal transplant patients.
Materials and methods

Literature search
A computerized literature search was performed to identify relevant studies in PubMed up to December 2009. Search terms included the following text words: '(CYP3A5 or Cytochrome P450 3A5) and (polymorphism or polymorphisms or genotype or genotypes or genetic) and (cyclosporine or cyclosporin or ciclosporin) and (kidney or renal) and (transplantation or transplant or allograft or graft)'. The search was not limited to any language. The titles and abstracts of potential articles were screened to determine their relevance, and any clearly irrelevant studies were excluded. The full texts of the remaining articles were read to determine whether they contained information on the topic of interest. Furthermore, reference lists of primary studies and review articles were also reviewed by a manual search to identify additional relevant publications.
Study selection
To include relevant studies in this meta-analysis, the following three criteria were used. First, CsA blood trough or peak concentrations were measured separately in subjects with three different genotypes, or separately in *3/*3 and *1/*3 þ *1/*1 genotypes. Second, the concentrations should be adjusted or could be estimated by corresponding 24-h dose on an mg per kg basis. Last, the result of each study was expressed as or could be estimated into mean and s.d.
The primary literature search identified 38 records in which there was an article indexed twice, resulting in a total of 37 articles. After screening the titles and abstracts, 10 articles were excluded because they were reviews or irrelevant to the current topic, 1 was excluded for the reason that all patients had the CYP3A5*3/*3 genotype in the study and 1 more was excluded because of the different single-nucleotide polymorphisms studied. The remaining 25 full texts were reviewed by two researchers. Six were excluded because they only evaluated the association of CYP3A5*3 polymorphism with patient survival, renal dysfunction or CsA oral clearance and not with CsA concentration. Three were excluded because the values of CsA concentrations were not shown and we could not obtain that from the researchers. Two studies, respectively, reporting the results as geometric mean with 95% confidence interval (CI) and median with inter-quartile range were excluded because these values could not be transformed or evaluated into means with s.d.'s. Finally, this meta-analysis included 14 articles; 8 of them only concerned trough concentrations and 3 only concerned peak concentrations, whereas 3 articles focused on both. A study performed by Kreutz et al. 16 was regarded as two studies because of the two different CsA assay methods applied. 
Data extraction
All data were extracted independently by two researchers using a recording form. The results were compared and the discrepancies in data abstraction were resolved through consensus. The following information was extracted from each article: the first author's name, year of publication, country of origin, interval since renal transplantation, quantified method of CsA concentration, sample size, the number of subjects with different CYP3A5 genotype, the mean and s.d. values of doseadjusted CsA trough or peak concentrations in different CYP3A5 genotype carriers. To allow for comparisons among the different dose levels, CsA concentrations were adjusted according to each subject's individual daily dose (mg kg -1 ). If results of a study were expressed as median and range, the mean and s.d. were estimated using the methods of Hozo et al. 17 When CsA concentration had been assayed more than once, the overall mean and s.d. were derived as described by Jiang et al.
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Statistical analysis
In the meta-analysis, the primary analysis was to evaluate the weighted mean difference (WMD) of C 0 /D and C 2 /D between CYP3A5 expressers (*1/*3 þ *1/*1) and non-expressers (*3/*3). The pooled estimates were obtained by combining the results of studies with a random-effects model (DerSimonian-Laird method) or a fixed-effects model (MantelHaenszel method). The heterogeneity of results in each meta-analysis was assessed using Q and I 2 statistics. The significance level was set at 0.10 instead of the traditional 0.05 level to guard against type II errors. If significant heterogeneity was found (Po0.10), the random-effects model, which considers both within-and between-study variations, was used for meta-analysis. Otherwise, the fixedeffects model was used. Sensitivity analysis was performed by analyzing the influence of each study on the overall estimates and heterogeneity. The combined WMDs from the fixed-and random-effects model were also compared to assess the stability of the results. Potential outliers were identified by the method of Huffcutt et al. 19 using sample-adjusted meta-analytic deviancy (SAMD) statistic. The absolute values of the SAMD statistics were sequenced from highest to lowest and then plotted. The initial values that lay well above the flat portion were considered to be outliers. Furthermore, to explore the possible sources of heterogeneity, the differences were also pooled in subgroups according to country of origin, CsA assay times, results expression (median or mean), CsA concentration quantified method and percentage of male subjects. Meta-regression was used to compare the difference of WMD within subgroups. Egger's test and Begg's test were conducted to assess publication bias and a Po0.10 was considered as significant. All the analyses were performed using Stata 10.0 software (STATA Corp., College Station, TX, USA). All statistical tests were two sided.
Results
Literature review
A total of 14 studies conducted between 2003 and 2009 with 1742 subjects were included in this meta-analysis, and the study performed by Kreutz et al. 16 was regarded as two studies. Five studies were from western countries, including France, the Netherlands, Belgium, United States and Germany, 14, 16, [20] [21] [22] whereas 9 were from Asian countries, of which 6 were from China, [11] [12] [13] [23] [24] [25] and the remaining 3 were performed in India, Singapore and Malaysia, respectively. [26] [27] [28] Most of the CsA administrations were multiple oral doses adjusted according to C 0 or C 2 levels. There were four studies that did not show the concentrations of *1/*1 and *1/*3 genotypes separately. 16, 23, 26 In addition, in the study of Haufroid et al., 21 there was no subject with *1/*1 genotype. Among all the subjects, the frequencies of CYP3A5*1/*1 þ *1/*3 (expresser) and *3/*3 (non-expresser) were 34.73 and 65.27%, respectively. Of the 15 studies, mean difference of C 0 /D was reported to be significant in 3 studies, 11, 24, 25 and the significance was also present in the study by Qiu et al., 12 whereas the intervals since transplantation were 8-15 days or 16-30 days. Most of the studies reported an increased C 0 /D level in *3/*3 genotype carriers. Inversely, Chu et al. 24 showed a significantly higher level among subjects with *1/*1 genotype. With regard to CsA peak concentration, mean difference was significant in the study by Yates et al. 22 and in the study by Singh et al., 26 whereas the interval was 3 months. Against the other studies, the results of Yates et al. 22 showed a decreased concentration in *3/*3 genotype when compared with *1/*1 þ *1/*3 genotype. The basic characteristics of each study are presented in Table 1 .
Effect on C 0 /D The pooled estimate of C 0 /D is shown in Figure 1 . The comparison between *1/*1 þ *1/*3 and *3/*3 genotype was investigated in 12 studies. Overall, there was significant heterogeneity among the studies concerning C 0 (Q ¼ 33.97, I 2 ¼ 67.62%, Po0.001). The combined WMD from the random-effects model was marginally significant with the difference of À3.75 (ng ml -1 )/(mg kg -1 ) (95% confidence interval (CI) À7.58 to 0.07, P ¼ 0.054). Publication bias was not found for WMD of C 0 /D (Begg's test:
The results of sensitivity analysis for C 0 /D are summarized in Table 2 . The study by Chu et al. 24 was found to obviously influence the combined WMD of C 0 /D. When that study was omitted, random-effects model showed a significant pooled estimate (WMD ¼ À4.92 (ng ml -1 )/(mg kg -1 ), 95% CI À8.27 to À1.58) and the heterogeneity was reduced (Q ¼ 22.99, I
2 ¼ 56.50%, P ¼ 0.011). A consequent sensitivity analysis including the remaining studies (without the study by Chu et al. 24 ) showed that no study had an essential influence on the combined results (data not shown). Potential outliers were identified using SAMD statistic. The screen plot also revealed that the study by Chu et al., 24 rising above an imaginary line formed by the remaining studies, was an outlier (SAMD ¼ 64.20; Figure 2 ).
Subgroup analysis of C 0 was also performed to explore the sources of heterogeneity. Subgroups were classified according to the characteristics of studies, including country of origin, CsA assay times, CsA concentration assay methods, The concentration of CsA was assayed more than once. The overall mean and s.d. were calculated as described by Jiang et al. results expression (mean or median) and percentage of male subjects ( Table 3 ). The analysis did not identify a factor that could affect the heterogeneity of C 0 /D. However, the association was emerged in the studies in which the concentrations of CsA were assayed more than once (WMD ¼ À4.30 (ng ml -1 )/(mg kg -1 ), 95% CI À8.09 to À0.51) and in the studies with the percentage of male subjects p61% (WMD ¼ À5.03 (ng ml -1 )/(mg kg -1 ), 95% CI À9.64 to À0.41). In addition, meta-regression was conducted to compare the estimates within the subgroups and no significance was found.
To evaluate the relationship between CYP3A5*3 polymorphism and C 0 /D in different intervals since transplantation (within 1 week, 1-3 months and over 6 months), we re-extracted data from the studies, and the results are shown in Table 4 . The pooled WMD was significant in the interval of within 1 week (WMD ¼ À3.75 (ng ml According to the sensitivity analysis for C 2 /D, the study by Yates et al. 22 showed a great effect on the combined results (Table 5 ). When this study was excluded, the pooled estimate from the fixed-effects model was essentially unchanged (WMD ¼ À15.69 (ng ml -1 )/(mg kg -1 ), 95% CI À28.37 to À3.02) and was consistent with that from the random-effects model. However, the homogeneity was obviously increased (Q ¼ 0.67, I 2 ¼ 0%, P ¼ 0.955). The screen plot of the absolute value of the SAMD statistics also indicated that the study by Yates et al. 22 was deemed an outlier (SAMD ¼ 31.92; Figure 4) . Because of the small number of studies, subgroup analysis was discarded.
Discussion
The CYP3A5*3 polymorphism was indicated to significantly affect the area under curve and apparent oral clearance (CL/F) of oral CsA in healthy subjects. 29 However, the most available clinical markers of CsA pharmacokinetics are its trough and peak levels. Although several studies have evaluated the effect of CYP3A5*3 polymorphism on the C 0 /D or C 2 /D, the results are controversial. Recent reviews also suggested that the association between CYP3A5*3 polymorphism and CsA pharmacokinetics is questionable. 10, 30 This study is the first meta-analysis evaluating Among the included studies, the frequency of CYP3A5*1 allele was ranged from 5.2 to 29.7%, whereas the study by Yates et al. 22 with a small sample size (n ¼ 10) showed an outlier of 55%. A marked ethnic diversity was shown with the CYP3A5*1 allele frequency of 18.3-29.3% in Chinese and 5.2-14.4% in western countries.
In the present quantitative study, the combined WMD of C 0 /D was found to be marginally significant (P ¼ 0.054) between CYP3A5 expressers and non-expressers. However, the heterogeneity across 12 studies about C 0 was statistically significant. Sensitivity analysis showed that the pooled results and the heterogeneity was influenced by the study of Chu et al., 24 whereas SAMD analysis indicated that it was an outlier. In the study by Chu et al., 24 the frequencies of CYP3A5 *1*1, *1*3 and *3/*3 were 8.8, 40.8 and 50.3%, respectively, which were consistent with the other studies performed in China. However, the C 0 /Ds of varied genotypes in this study apparently differed from others. The C 0 /D level was significantly higher in *1/*1 genotype when compared with *3/*3 genotype. Theoretically, *3 allele, inducing the silence of protein activity and classified as CYP3A5 non-expresser, would probably elevate the C 0 /D level. Because of the relatively large sample size, the extreme results of Chu et al. 24 may not occur from large sampling errors and represented a potential outlier. After excluding this study, a concomitant shift in heterogeneity was shown (from I 2 ¼ 67.62 to I 2 ¼ 56.50) and the results from randomeffects model showed a significant WMD, indicating an effect of CYP3A5*3 polymorphism on C 0 /D. The consequent sensitivity analysis without the study by Chu et al. The subgroups were classified according to the median of male percentage (61%). revealed that the summary estimate was relatively stable and confident. Although the remaining heterogeneity was moderately present, it was acceptable and was taken into account by random-effects model. Thus, the effect of CYP3A5*3 polymorphism on C 0 /D is plausible.
In addition, subgroup analysis was conducted by factors available in most studies to explore the possible sources of heterogeneity. Results did not imply a factor that could influence the heterogeneity. Obviously, most of the subgroups, including the study of Chu et al., 24 showed a significant heterogeneity. An association was found in the subgroup in which the concentrations of CsA were assayed more than once and also in the studies with the percentage of male subjects p61%. Both the subgroups did not include the study by Chu et al., 24 and the number of studies was relative large. Actually, in the subgroups of 'Asian countries', 'CsA assay once', 'results expression by mean' and 'quantified method by fluorescence polarization immunoassay (FPIA)' with large sample size, the significant WMDs were also present if the study by Chu et al. 24 was excluded. Under the condition, it was noted that the pooled estimate was significant in both the subgroups classified according to CsA assay times, as both the sample size were at least 5. Therefore, the associations might be shown in case of large sample size and excluding the study performed by Chu et al. 24 In addition, meta-regression did not indicate a significant result, confirming the absence of difference within subgroups.
With regard to the C 2 /D, the study by Yates et al.
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showed a great influence on the combined WMD and the heterogeneity. 22 It should be noted that the sample size in the study of Yates et al. 22 was very small (n ¼ 10), and the extreme results was suggested to be an artifact that was supported by the finding of linkage between CYP3A5 nonexpressers and multidrug resistance (MDR1) 3435T allele carriers. Without this study, the pooled WMD was essentially unchanged and the homogeneity was increased. Meanwhile, the consistence was shown in fixed-and random-effects models, indicating that the combined estimate was stable. Although the combined result of C 2 /D is only based on six studies, our results suggested an effect of CYP3A5 genotype on the CsA peak concentrations adjusted by daily dose.
In addition, the intervals since transplantation were varied among the studies. And the concentrations of CsA were assayed more than once in several studies. Qiu et al. 12 evaluated the association between the polymorphism and dose-adjusted CsA concentration in 1-7 days, 8-15 days and 16-30 days. It was found that CYP3A5 genotypes have effects on CsA concentration in 8-30 days but not in 1-7 days after transplantation. Patients were more likely to have gastrointestinal dysfunction and may receive more comedication in the first week after the surgery than in 8-30 days, which were suggested to mask the influence of the polymorphism on the pharmacokinetics. Eng et al., 28 Hesselink et al.
14 and Zhao et al. 23 also respectively obtained the data of CsA levels at different months after transplantation. However, no influence of intervals since transplantation was reported on the association between CYP3A5 genotypes and CsA levels adjusted by daily dose. We reextracted the data from the studies and classified them into three subgroups (within 1 week, 1-3 months and over 6 months). The pooled WMD was only significant in the subgroup of within 1 week. However, the number of studies in this subgroup was limited (n ¼ 4), and the result should be confirmed by including more studies.
Limitations also inevitably existed in this meta-analysis. First, only articles indexed in PubMed were included.
Limited resources kept us from accessing unpublished studies. Thus, the potential selection bias might affect the results. Second, the heterogeneity of combined WMD of C 0 /D across studies was significant, despite that the outlier study was excluded. The source may be from the discrepant factors of studies in terms of country of origin, assay times, assay methods and so on. However, none of such factors was found to influence the heterogeneity through subgroup analyses and meta-regressions. Nevertheless, the summarized estimates of C 0 /D pooled from the random-effects model allows the heterogeneity to be taken into account. Third, the dose-adjusted concentrations in some studies were summarized as median and range. Estimations of mean and s.d. were performed as previously described. This conversion may have introduced bias in the subsequent analyses. Anyhow, the methods described by Hozo et al. 17 were shown to be robust and distribution-free through simulation models and illustrative examples. Fourth, we estimated an overall mean and s.d. using the methods of Jiang et al., 18 when CsA concentrations were determined at different intervals since transplantation in a study. The combined results may be affected by such estimations. Thus, we performed a subgroup analysis to analyze the influence of post-transplantation time. Fifth, other gene polymorphisms such as MDR1 C1236T have also been reported to contribute to CsA pharmacokinetics. The pooled estimates may also be influenced by gene-gene interactions. As few studies focused on the same interaction pairs, the metaanalysis of gene-gene interactions is inaccessible. Last, the number of the available studies included in our metaanalysis is relatively limited. Because of the above limitations in the meta-analysis, the pooled estimates should be interpreted with caution and further research is needed.
In conclusion, this meta-analysis indicated a significant effect of CYP3A5*3 polymorphism on both CsA C 0 /D and C 2 /D in renal transplant recipients. Now in clinic, CsA administration was routinely individuated based on therapeutic drug monitoring. However, this method has several limitations. Because of the inter-individual variable bioavailability, the dose requirement may also differ even if the concentrations before adjustment were identical in individuals. Our results provide evidence that CYP3A5 genotyping could be taken into account for CsA dosing in renal transplant recipients. Patients carrying the CYP3A5*3/*3 genotype will require a lower dose of CsA to achieve the same blood concentrations when compared with the CYP3A5*1/*1 or *1/*3 carriers. With the future population pharmacokinetic research incorporating genotype information, the dose prediction could be more accurate. 31 In addition, CsA administration based on therapeutic drug monitoring can only be applied after the start of drug treatment. CYP3A5 genotyping before renal transplantation may contribute to a better individualization and optimization of CsA initial dose.
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